Lilly Insulin Tops Sanofi's Lantus in Trials; Liver Issue PersistsLilly Insulin Tops Sanofi's Lantus in Trials; Liver Issue Persists

A long-acting insulin being developed by Eli Lilly and Co demonstrated greater blood sugar reduction than Sanofi SA's top-selling Lantus in patients with type 2 diabetes, according to data from three Phase III trials presented on Saturday. Reuters Health Information
Source: Medscape Diabetes Headlines - Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news